Who makes Moderate Dose Quillivant XR?

Moderate Dose Quillivant XR is developed by Seattle Children's Hospital.

What development phase is Moderate Dose Quillivant XR in?

Moderate Dose Quillivant XR is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Moderate Dose Quillivant XR

Seattle Children's Hospital · FDA-approved active Small molecule Quality 1/100

At a glance

Generic name	Moderate Dose Quillivant XR
Also known as	Methylphenidate HCl
Sponsor	Seattle Children's Hospital
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Moderate Dose Quillivant XR CI brief — competitive landscape report
Moderate Dose Quillivant XR updates RSS · CI watch RSS
Seattle Children's Hospital portfolio CI